Displaying items by tag: Oxford University

Education secretary Nadhim Zahawi said Oxford University should explain to Jewish students why it took a total of £12.3 million from the Mosley family, as anti-Semitism is not simply a historic debate. The Mosley charitable trust houses the fortune of Sir Oswald Mosley, leader of the British Union of Fascists. The university is now facing a donor backlash. One benefactor vowed not to give St Peter’s College another penny, and four British Nobel laureates have urged the university to reconsider giving a professorship in the name of Mosley’s grandson, saying that doing so ‘dishonours’ their subject. On 9 November police were called to the London School of Economics, where activists carrying Palestinian flags demonstrated against Israel’s ambassador, who was addressing the university's debating society. They chanted that Israel is a ‘terrorist state’. Next week the debating society is hosting Husam Zomlot, head of the Palestinian mission to the UK.

British scientists have identified a gene that doubles the risk of dying from Covid-19, opening up possibilities for targeted medicine and providing new insights into why some people are more susceptible to the disease than others. Researchers at Oxford University found that 60% of people with South Asian ancestry carry the high-risk gene. The discovery partly explains the high number of deaths seen in some British communities, and the effect of Covid in the Indian subcontinent. The scientists found that the increased risk is not because of a difference in genetic coding of the proteins, but because of differences in the DNA that makes a kind of ‘switch’ to turn a gene on. That genetic signal is likely to affect cells in the lung. The study shows that the way in which the lung responds to the infection is critical. This is important because most treatments have focused on changing the way in which the immune system reacts to the virus.

The UK has ordered five million doses of vaccine from the US company Moderna and 40 million of the Pfizer jab. Moderna said its vaccine may be 94.5% effective against the virus, while Pfizer suggested theirs had an efficacy of 90%. Both vaccines use the same technology which gives the vaccinated person’s body the genetic instructions for their own cells to produce the antigens and generate an immune response. The trials are ongoing and final numbers could change. Moderna vaccine is much easier to distribute than the Pfizer jab which must be kept at -100C to maintain optimal efficacy causing concerns around the storage. The Moderna vaccine lasts 30 days in household fridges, 12 hours at room temperature and remains stable at -20C (equal to most freezers) for six months. The choice has been complicated by an announcement on 19 November that the vaccine being developed by Oxford University could be ready for use by Christmas. See

Professor Sarah Gilbert, the world-renowned expert leading Oxford University’s team devising a vaccine, told MPs that it would provide ‘a good duration of immunity for several years at least, and probably be better than naturally-acquired immunity.’ Asked for a timeline on the vaccine amid concerns of facing the winter without one, she said, ‘I hope we can improve on those timelines and come to the rescue.’ 8,000 Britons are in a major trial of the Oxford vaccine, and an experimental vaccine is being tested by a German partner. These trials showed encouraging early results, producing neutralising antibodies between 1.8 and 2.8 times greater than those of recovered patients. The key question is whether the vaccine will protect people from becoming infected, or simply make them less ill. It may also work less well in older people because their immune systems are weaker.